We are pleased to announce our participation in the World ADC Congress, taking place in London, UK, from February 23 to 26.
Widely regarded as the leading global event focused on antibody–drug conjugates (ADCs), the congress unites key stakeholders from across the entire ADC value chain — spanning early discovery, linker–payload innovations, and clinical translation.
During the event, Anne Chevrel will disclose new preclinical data on our lead pH-sensitive antibody–drug conjugate, showcasing our expertise in targeted delivery and enhanced therapeutic efficacy.
Our delegation will include:
• Anne Chevrel, Head of Discovery & Technology
• Sylvain Yon, CEO
• Cécile Durand, Business Development Director
We look forward to engaging with the global ADC community and discussing innovative strategies shaping the next generation of antibody–drug conjugates.
For more information or to meet us during the congress, feel free to contact our team : Contact WORLD ADC congress 2026 – Mabqi
